Technical Analysis for AZN - Astrazeneca PLC

Grade Last Price % Change Price Change
D 65.85 -0.69% -0.46
AZN closed down 0.69 percent on Monday, March 18, 2024, on 59 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Up Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
200 DMA Support Bullish -0.69%
Gapped Up Strength -0.69%
Overbought Stochastic Strength -0.69%
Bearish Engulfing Bearish -1.78%
Cup with Handle Other -1.78%
Overbought Stochastic Strength -1.78%
Shooting Star Candlestick Bearish -2.56%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 14 hours ago
60 Minute Opening Range Breakout about 17 hours ago
200 DMA Support about 19 hours ago
200 DMA Resistance about 19 hours ago
Fell Below 200 DMA about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Astrazeneca PLC Description

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics; and a strategic collaboration with FibroGen, Inc. to develop and commercialize FG-4592, a compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Cancer Nasdaq 100 Acid Drugs Antibodies Neuroscience Monoclonal Antibodies Inflammation Breast Cancer Infection Gastrointestinal Hypertension Psychoactive Drugs Inflammatory Diseases Kidney Disease Heart Failure Schizophrenia Coronavirus Asthma Major Depressive Disorder Chronic Obstructive Pulmonary Disease Respiratory Diseases Anemia Cholesterol Pulmonary Disease Depressive Disorder Primary Care Chronic Kidney Disease End Stage Renal Disease Chronic Condition Renal Disease Stage Renal Disease Autoimmune And Inflammatory Disease Bipolar Disorder Pulmonology Angina Nanomedicine Respiratory Infection Inflammation Diseases Linaclotide

Is AZN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 74.9096
52 Week Low 59.5549
Average Volume 6,605,798
200-Day Moving Average 66.15
50-Day Moving Average 65.38
20-Day Moving Average 65.70
10-Day Moving Average 66.46
Average True Range 1.01
RSI (14) 51.69
ADX 16.06
+DI 30.94
-DI 26.60
Chandelier Exit (Long, 3 ATRs) 64.99
Chandelier Exit (Short, 3 ATRs) 63.87
Upper Bollinger Bands 68.02
Lower Bollinger Band 63.37
Percent B (%b) 0.53
BandWidth 7.08
MACD Line 0.60
MACD Signal Line 0.49
MACD Histogram 0.1083
Fundamentals Value
Market Cap 204.16 Billion
Num Shares 3.1 Billion
EPS 1.91
Price-to-Earnings (P/E) Ratio 34.48
Price-to-Sales 4.14
Price-to-Book 5.03
PEG Ratio 0.49
Dividend 2.90
Dividend Yield 4.40%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 66.70
Resistance 3 (R3) 66.78 66.57 66.56
Resistance 2 (R2) 66.57 66.36 66.53 66.51
Resistance 1 (R1) 66.21 66.22 66.11 66.13 66.46
Pivot Point 66.01 66.01 65.96 65.97 66.01
Support 1 (S1) 65.65 65.79 65.55 65.57 65.24
Support 2 (S2) 65.44 65.66 65.40 65.19
Support 3 (S3) 65.08 65.44 65.14
Support 4 (S4) 65.00